Patient characteristics
| . | All, n (%) . | Axi-cel . | Tisa-cel . | P . |
|---|---|---|---|---|
| Patients infused | 356 | 173 | 183 | |
| Median age (range) | 60 (19-83) | 60 (20-83) | 61 (19-83) | n.s. |
| Male | 236 (66) | 120 (69) | 116 (64) | n.s. |
| Histology | ||||
| DLBCL | 323 (91) | 153 (88) | 170 (93) | .004 |
| PMBCL | 16 (5) | 14 (8) | 2 (1) | |
| tFL/Other | 17 (5) | 6 (4) | 11 (6) | |
| Interval indication to CAR T-cell infusion (d) | 68 (28-278) | 65 (28-278) | 68 (28-194) | n.s. |
| Interval leukapheresis to CAR T-cell infusion (d) | 42 (27-526) | 35 (27-133) | 55 (27-526) | <.001 |
| sIPI high/high-intermediate | 171 (52) | 92 (47) | 79 (57) | n.s. |
| LDH >N at LD | 213 (60) | 112 (65) | 101 (55) | n.s. |
| ECOG ≥2 | 56 (16) | 27 (16) | 29 (16) | n.s. |
| ≥3 Treatment lines | 252 (71) | 116 (67) | 136 (74) | n.s. |
| Prior HCT % | 121 (34) | 57 (33) | 64 (35) | n.s. |
| Bridging | 278 (78) | 125 (72) | 153 (84) | .017 |
| None | 76 (22) | 47 (27) | 29 (17) | |
| Response (CR/PR) | 59 (17) | 22 (13) | 37 (21) | |
| No Response | 210 (61) | 103 (60) | 108 (62) | |
| Refractory at LD | 213 (60) | 92 (53) | 121 (66) | .013 |
| Eligibility ZUMA-I | 45 (13) | 31 (18) | 14 (8) | .004 |
| Eligibility JULIET | 318 (89) | 149 (86) | 169 (92) | n.s. |
| . | All, n (%) . | Axi-cel . | Tisa-cel . | P . |
|---|---|---|---|---|
| Patients infused | 356 | 173 | 183 | |
| Median age (range) | 60 (19-83) | 60 (20-83) | 61 (19-83) | n.s. |
| Male | 236 (66) | 120 (69) | 116 (64) | n.s. |
| Histology | ||||
| DLBCL | 323 (91) | 153 (88) | 170 (93) | .004 |
| PMBCL | 16 (5) | 14 (8) | 2 (1) | |
| tFL/Other | 17 (5) | 6 (4) | 11 (6) | |
| Interval indication to CAR T-cell infusion (d) | 68 (28-278) | 65 (28-278) | 68 (28-194) | n.s. |
| Interval leukapheresis to CAR T-cell infusion (d) | 42 (27-526) | 35 (27-133) | 55 (27-526) | <.001 |
| sIPI high/high-intermediate | 171 (52) | 92 (47) | 79 (57) | n.s. |
| LDH >N at LD | 213 (60) | 112 (65) | 101 (55) | n.s. |
| ECOG ≥2 | 56 (16) | 27 (16) | 29 (16) | n.s. |
| ≥3 Treatment lines | 252 (71) | 116 (67) | 136 (74) | n.s. |
| Prior HCT % | 121 (34) | 57 (33) | 64 (35) | n.s. |
| Bridging | 278 (78) | 125 (72) | 153 (84) | .017 |
| None | 76 (22) | 47 (27) | 29 (17) | |
| Response (CR/PR) | 59 (17) | 22 (13) | 37 (21) | |
| No Response | 210 (61) | 103 (60) | 108 (62) | |
| Refractory at LD | 213 (60) | 92 (53) | 121 (66) | .013 |
| Eligibility ZUMA-I | 45 (13) | 31 (18) | 14 (8) | .004 |
| Eligibility JULIET | 318 (89) | 149 (86) | 169 (92) | n.s. |
ECOG, Eastern Cooperative Oncology Group performance status; HCT, hematopoietic cell transplantation; IPI, International Prognostic Index; LD, lymphodepletion; LDH, lactate dehydrogenase; N, normal; n.s., not significant; PMBCL, primary mediastinal B-cell lymphoma; tFL, transformed follicular lymphoma.